Based on a cohort of MM patients from publicly available NCBI Gene Expression Omnibus (GES5900 and GSE2658) (Fig. 1a), we found that SFXN2 mRNA was significantly increased in MM cells compared to normal bone marrow plasma cells (NP) as well as the “premalignant” ones with monoclonal gammopathy of undetermined significance (MGUS) (Fig. 1b). This evidence concerns the gene SFXN2 and Miyoshi myopathy.